| 2026-08-11 | Deck | Neurogene Corporate Presentation August 2026 |
| 2026-08-11 | Press release | Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates |
| 2026-08-11 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-11 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-08-04 | Press release | Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-07-06 | Press release | Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-07-02 | 8-K | Form 8-K, Item 1.01 |
| 2026-07-01 | Press release | Neurogene Inc. Announces Pricing of $125 Million Public Offering |
| 2026-06-30 | Press release | Neurogene Inc. Announces Proposed Public Offering |
| 2026-06-29 | Deck | NGN-401 Phase 1/2 Clinical Data Update June 2026 |
| 2026-06-29 | Press release | Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome |
| 2026-06-29 | 8-K | Form 8-K, Item 7.01 |
| 2026-06-13 | Press release | Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates |
| 2026-06-09 | Press release | Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates |
| 2026-06-08 | Press release | Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome |
| 2026-06-08 | 8-K | Form 8-K, Item 7.01 |
| 2026-06-07 | Press release | Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates |
| 2026-06-06 | Press release | Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates |
| 2026-06-04 | 8-K | Form 8-K, Item 5.07 |
| 2026-06-02 | Press release | Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-05-12 | Press release | Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates |
| 2026-05-12 | Press release | Neurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method in CNS-targeted Gene |
| 2026-05-12 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-12 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-05-06 | Press release | PDF Version |
| 2026-05-06 | Press release | Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-04-28 | Press release | PDF Version |
| 2026-04-28 | Press release | Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy |
| 2026-04-20 | Press release | PDF Version |
| 2026-04-20 | Press release | Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors |
| 2026-04-20 | 8-K | Form 8-K, Item 5.02 |
| 2026-04-16 | Proxy | Definitive proxy statement |
| 2026-04-08 | Press release | PDF Version |
| 2026-04-08 | Press release | Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-03-24 | Press release | Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates |
| 2026-03-24 | 8-K | Form 8-K, Item 2.02 results |
| 2026-03-24 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-03-11 | Press release | PDF Version |
| 2026-03-03 | Press release | PDF Version |
| 2026-03-03 | Press release | Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |